Imaging for Oncologic Response Assessment in Lymphoma. AJR Am J Roentgenol 2017 Jan;208(1):18-31
Date
10/28/2016Pubmed ID
27786547DOI
10.2214/AJR.16.16180Scopus ID
2-s2.0-85007332280 (requires institutional sign-in at Scopus site) 28 CitationsAbstract
OBJECTIVE: The purpose of this article is to examine the role of different imaging biomarkers, focusing in particular on the use of updated CT and PET response criteria for the assessment of oncologic treatment effectiveness in patients with lymphoma but also discussing other potential functional imaging methods and their limitations.
CONCLUSION: Lymph nodes are commonly involved by metastatic solid tumors as well as by lymphoma. Evolving changes in cancer therapy for lymphoma and metastases have led to improved clinical outcomes. Imaging is a recognized surrogate endpoint that uses established criteria based on changes in tumor bulk to monitor the effects of treatment. With the introduction of targeted therapies and novel antiangiogenic drugs, the oncologic expectations from imaging assessment are changing to move beyond simple morphologic methods. Molecular and functional imaging methods (e.g., PET, perfusion, DWI, and dual-energy CT) are therefore being investigated as imaging biomarkers of response and prognosis. The role of these advanced imaging biomarkers extends beyond measuring tumor burden and therefore might offer insight into early predictors of therapeutic response. Despite the potential benefits of these exciting imaging biomarkers, several challenges currently exist.
Author List
Kulkarni NM, Pinho DF, Narayanan S, Kambadakone AR, Abramson JS, Sahani DVAuthor
Naveen Kulkarni MBBS Associate Professor in the Radiology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Diffusion Magnetic Resonance ImagingHumans
Lymphoma
Molecular Imaging
Positron-Emission Tomography
Tomography, X-Ray Computed
Treatment Outcome
